Dana-Farber researchers to lead collaborative smallpox studies

September 17, 2003

BOSTON--The National Institute of Allergy and Infectious Diseases (NIAID) announced today that it has selected Dana-Farber Cancer Institute to head one of five newly established Cooperative Centers for Translational Research on Human Immunology and Biodefense.

Investigators at Dana-Farber and their colleagues from other Harvard Medical School-affiliated hospitals and the University of Massachusetts Medical School will receive a $15.1 million grant over 4 1/2 years to fund research on a safer vaccine against the smallpox virus, an agent that has raised concerns as a potential bioterror weapon.

NIAID is committing approximately $85 million to develop the Cooperative Centers, a biodefense research network that focuses on the immune system. Investigators from the Cooperative Centers will work closely on projects to improve the nation's ability to respond to a biological terror attack. The goal of the research is to develop a better understanding of how the human immune system responds to disease-causing organisms, whether they are deliberately released or naturally occurring.

The Dana-Farber grant will support studies probing the body's immune response to the virus used in the current smallpox vaccine and to other viruses that may offer safer alternatives. The current vaccine, which is credited with eradicating smallpox around the world but hasn't been in general use in the United States since the early 1970s, uses a vaccinia virus - a cousin of the smallpox virus - to prompt an immune response that protects against smallpox. Though effective, the vaccine can cause serious complications in people with weakened immune systems, such as cancer and AIDS patients, or with skin diseases such as eczema.

"The aim of our research is to understand, in precise detail, the nature of the human immune system's response to the vaccinia virus and to other related viruses that potentially could be used as vaccines," says Dana-Farber's Ellis Reinherz, M.D., who is the principal investigator of the grant and a professor of medicine at Harvard Medical School. "Once we determine the mechanism by which the vaccine builds immunity and, in some cases, produces complications, we'll be in a position to develop effective alternatives that carry fewer risks."
In addition to Reinherz, the grant's project leaders are Raphael Dolin, M.D., Dean for Academic and Clinical Programs at Harvard Medical School and the Maxwell Finland Professor of Medicine at Brigham and Women's Hospital; Jerome Ritz, M.D., director of the Connell O'Reilly Cell Manipulation and Gene Transfer Laboratory at Dana-Farber; Thomas Kupper, M.D., the Thomas B. Fitzpatrick Professor of Dermatology at Brigham and Women's Hospital; Elliott Kieff, M.D., Ph.D., the Harriet Ryan Albee Professor of Medicine at Brigham and Women's Hospital; and Raymond Welsh, Ph.D., professor of pathology and professor of molecular genetics and microbiology at the University of Massachusetts Medical School in Worcester, Mass.

NIAID is a component of the National Institutes of Health, which is an agency of the Department of Health and Human Services. NIAID supports basic and applied research to prevent, diagnose and treat infectious and immune-mediated illnesses, including HIV/AIDS and other sexually transmitted diseases, illness from potential agents of bioterrorism, tuberculosis, malaria, autoimmune disorders, asthma and allergies.

Dana-Farber Cancer Institute is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.

Dana-Farber Cancer Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.